Jonakayem Pharma Formulation (OPC) Pvt. Ltd.
DACARBAZINE

DACARBAZINE

Send Inquiry
Sub Group Generic Formulary Brand Name Dosages Unit In treatment of Adverse Effects Contraindication Special Precaution Interaction Servings

DACARBAZINE DTIC, DTIC-Dome 100 MG/ 200 mg/500 mg Vial TREATMENT OF MESTATIC MALIGNANT MELANOMA 1. Nausea
2. Vomiting
3. Lowered resistance to infection
4. Bruising or unusual bleeding
5. Anemia
6. Weakness
7. Sore in mouth
8. Taste changes
9. Diarrhea
10. Loss of appetite
11. Visual changes
12. Black, tarry stools
13. Blood in urine or in stool
14. Cough or hoarseness
15. Fever
16. Chills
17. Lower back or side pain
18. Painful or difficult urination
19. Pinpoint red spot on skin
20. Slurred speech
21. Swelling on leg or lower leg
22. Shortness of breath
23. Pulmonary fibrosis
24. Hepatotoxicity
25. Nephrotoxicity
26. Stomatitis
27. Disorientation
28. Lethargy
29. Ataxia
30. Thrombocytopenia
31. Leucopenia
32. Bone marrow suppression
33. Alopecia
34. Urticaria
35. Photosensitivity
36. Hepatic necrosis
37. Renal impairment
38. Flu like syndrome
39. Myalgia
1. Hypersensitivity to the drug
2. Bone marrow suppression
1. Impaired bone marrow function
2. Hepatic impairment
3. Renal impairment
4. Monitor haematological functions regularly
5. Restricted the food intake before the drug administration.

Intravenous-
Adult-
Metastatic malignant melanoma: 2-4.5mg/kg/day for 10 days, repeat the treatment every 4 weeks OR 250mg/metre square /day for 5 days, repeated every 3 weeks.
Hodgkin`s disease-150mg/metre square for 5 days, repeat every 4 weeks OR 375mg/metre square on day 1of a combination regimen, repeat every 15 days